Cost-effectiveness analysis

The goal of CEA is to determine the most effective way of using limited resources to achieve meaningful clinical outcomes, i.e quality-adjusted life years (QALYs). Typically, this is done by calculating the incremental cost-effectiveness ratio (ICER). It reflects the cost of an additional unit of effect, such as QALY, when using a more expensive and more effective drug, compared to a less costly and less effective therapy option. For a drug to be recommended for inclusion in the lists, such cost must be acceptable to the payer - government, insurance company or medical facility.

Our team is a reliable partner for most major international pharmaceutical companies in conducting CEA for drugs. Since 2019, cost-effectiveness and budget impact studies performed by our team were used for 32 submissions for inclusion of drugs for treatment of cancer, blood, brain, kidney and other diseases into reimbursement lists in Russia. Out of these submissions, 18 drugs were approved for inclusion in the Essential Medicines list and 6 for inclusion in the High-Cost Drugs program.

Our team is open to new projects for conducting cost-effectiveness evaluations of drugs. If your company requires CEA to support the inclusion of a drug in the reimbursement lists, please contact us and we will make every effort to address your challenges!